Clostridium difficile 감염의 역학 및 치료

키워드

참고문헌 (44)

1. Warny M, "Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe", Lancet, 366, pp.1079~1084 (2005)
2. Clements AC, "Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread", Lancet Infect Dis, 10, pp.395~404 (2010)
3. Bartlett JG, "Clinical recognition and diagnosis of Clostridium difficile infection", Clin Infect Dis, 46(Suppl 1), pp.S12~S18 (2008)
4. Kirkpatrick ID, "Evaluating CT diagnosis of Clostridium difficile colitis: should CT guide therapy?", AJR Am J Roentgenol, 176, pp.635~639 (2001)
5. Owens RC Jr, "Antimicrobial-associated risk factors for Clostridium difficile infection", Clin Infect Dis, 46(Suppl 1), pp.S19~S31 (2008)
6. McDonald LC, "Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003", Emerg Infect Dis, 12, pp.409~415 (2006)
7. Thibault A, "Risk factors for the development of Clostridium difficile ?", Infect Control Hosp Epidemiol, 12, pp.345~348 (1991), associated diarrhea during a hospital outbreak
8. Dial S, "Use of gastric acidsuppressive agents and the risk of community-acquired Clostridium difficile -associated disease", JAMA, 294, pp.2989~2995 (2005)
9. Kyne L, "Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A", New Engl J Med, 342, pp.390~397 (2000)
10. Belmares J, "Molecular epidemiology of Clostridium difficile over the course of 10 years in a tertiary care hospital", Clin Infect Dis, 49, pp.1141~1147 (2009)
11. Muto CA, "A large outbreak of Clostridium difficile -associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use", Infect Control Hosp Epidemiol, 26, pp.273~280 (2005)
12. Pepin J, "Mortality attributable to nosocomial Clostridium difficile -associated disease during an epidemic caused by a hypervirulent strain in Quebec", CMAJ, 173, pp.1037~1042 (2005)
13. Rouphael NG, "Clostridium difficile -associated diarrhea: an emerging threat to pregnant women", Am J Obstet Gynecol, 198(635), pp.e1~e6 (2008)
14. Kim J, "A Prospective Study For Clostridium difficile Associated Diarrhea In Korea", IDSA, 1023~ (2009)
15. 변태준, "Clostridium difficile-Associated Disease (CDAD)의 최근 임상양상의 변화", 대한소화기학회지, 54(1), pp.13~19 (2009), 대한소화기학회
16. 김희정, "Investigation of Toxin Gene Diversity, Molecular Epidemiology, and Antimicrobial Resistance of Clostridium difficile Isolated from 12 Hospitals in South Korea", The Korean Journal of Laboratory Medicine, 30(5), pp.491~497 (2010), 대한진단검사의학회
17. Warny M, "Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe", Lancet, 366, pp.1079~1084 (2005)
18. McDonald LC, "An epidemic, toxin gene-variant strain of Clostridium difficile", N Engl J Med, 353, pp.2433~2441 (2005)
19. O'Connor D, "Evaluation of methods for detection of toxins in specimens of feces submitted for diagnosis of Clostridium difficile -associated diarrhea", J Clin Microbiol, 39, pp.2846~2849 (2001)
20. Snell H, "Performance of the TechLab C. DIFF CHEK-60 enzyme immunoassay (EIA) in combination with the C. difficile Tox A", B II EIA kit, the Triage C. difficile panel immunoassay, and a cytotoxin assay for diagnosis of Clostridium difficile -associated diarrhea, 2004, pp.42, 4863~4865
21. Ticehurst JR, "Effective detection of toxigenic Clostridium difficile by a twostep algorithm including tests for antigen and cytotoxin", J Clin Microbiol, 44, pp.1145~1149 (2006)
22. , 2010
23. Cohen SH, "Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)", Infect Control Hosp Epidemiol, 31, pp.431~455 (2010), Society for Healthcare Epidemiology of America
24. Teasley DG, "Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile -associated diarrhoea and colitis", Lancet, 2, pp.1043~1046 (1983)
25. Musher DM, "Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole", Clin Infect Dis, 40, pp.1586~1590 (2005)
26. Zar FA, "A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile -associated diarrhea, stratified by disease severity", Clin Infect Dis, 45, pp.302~307 (2007)
27. Louie TJ, "Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile -associated diarrhea (CDAD) in Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy", pp.K-425a~ (2007)
28. Pepin J, "Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada", Clin Infect Dis, 40, pp.1591~1597 (2005)
29. Wenisch C, "Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile -associated diarrhea", Clin Infect Dis, 22, pp.813~818 (1996)
30. Musher DM, "Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study", Clin Infect Dis, 48, pp.e41~e46 (2009)
31. Lagrotteria D, "Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile -associated diarrhea", Clin Infect Dis, 43, pp.547~552 (2006)
32. Johnson S, "Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment", Anaerobe, 15, pp.290~291 (2009)
33. Louie T, "A randomized, double-blind clinical trial of OPT-80 versus vancomycin in Clostridium difficile infection iun Program and abstracts of the 19th European Congress of Clinical Microbiology and Infectious Diseases", pp.0148~ (2009), ECCMID
34. Louie TJ, "OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection", Antimicrob Agents Chemother, 53, pp.261~263 (2009)
35. Barker RH Jr, "Review article: tolevamer, a novel toxin-binding polymer: overview of preclinical pharmacology and physiochemical properties", Aliment Pharmacol Ther, 24, pp.1525~1534 (2006)
36. Louie TJ, "Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile - associated diarrhea", Clin Infect Dis, 43, pp.411~420 (2006)
37. Bouza E, "Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile -associated diarrhoea in The18th European congress of clinical microbiology and infectious diseases", pp.0464~ (2008), ECCMID
38. Baines SD, "Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection", Antimicrob Agents Chemother, 53, pp.2202~2204 (2009)
39. McFarland LV, "Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease", Am J Gastroenterol, 101, pp.812~822 (2006)
40. Pillai A, "Probiotics for treatment of Clostridium difficile -associated colitis in adults. Cochrane Database Syst Rev 2008;CD004611", ~ (2008)
41. Lowy I, "Treatment with monoclonal antibodies against Clostridium difficile toxins", N Engl J Med, 362, pp.197~205 (2010)
42. Gerding DN, "Management of Clostridium difficile infection: thinking inside and outside the box", Clin Infect Dis, 51, pp.1306~1313 (2010)
43. Bakken JS, "Fecal bacteriotherapy for recurrent Clostridium difficile infection", Anaerobe, 15, pp.285~289 (2009)
44. Khoruts A, "Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile -associated diarrhea", J Clin Gastroenterol, 44, pp.354~360 (2010)

관련 논문AI추천